Entrada Therapeutics (NasdaqGM:TRDA) 2026 Conference February 11, 2026 04:00 PM ET Company ParticipantsDipal Doshi - CEOConference Call ParticipantsDebjit Chattopadhyay - Managing Director and Senior Biotech AnalystDebjit ChattopadhyayAfternoon, and thank you for joining us at Guggenheim's 2026 Emerging Outlook Biotech Summit. I'm Debjit, one of the therapeutic analysts, and next presenting company is Entrada Therapeutics. Joining us from Entrada is the CEO, Dipal Doshi. Thank you so much for making time fo ...

Summary of Neumora Therapeutics Conference Call Company Overview - **Company**: Neumora Therapeutics (NasdaqGS: NMRA) - **Event**: Guggenheim Emerging Outlook Biotech Summit, 2026 - **Date**: February 11, 2026 Key Points Industry and Product Focus - Neumora is focused on developing NMRA-511, a treatment for agitation in Alzheimer's disease (AD) [2][3] - The company is also exploring NLRP3 inhibitors for obesity and other indications [24][26] Clinical Data and Efficacy - NMRA-511 showed a significant clinical effect in a phase 1B study for AD agitation, achieving a 20.1-point reduction on the CMAI total score at week 8, with a Cohen's D effect size of 0.51-0.64 [5] - The CMAI aggression subfactor score for elevated anxiety populations had a robust effect size of 0.82 [6] - The CGI-S agitation score indicated a clinical effect size of 0.78 at week 6 and 0.38 at week 8, supporting the drug's potential [7] - NMRA-511 demonstrated a favorable safety and tolerability profile, allowing for higher dose testing planned for 2026 [8] Future Development Plans - Neumora plans to initiate a MAD extension cohort for NMRA-511 in 2026, transitioning to a QD extended-release formulation [9] - A pivotal phase 2/3 program is expected to start in 2027 [9] Market Opportunity - Approximately 60%-70% of Alzheimer's patients experience agitation and anxiety, indicating a significant market opportunity for NMRA-511 [10][11] - The company aims to enrich patient populations in pivotal studies to enhance treatment efficacy [11] Competitive Landscape - Competitors include Newleos and Azevan, which are also exploring treatments for anxiety and agitation [19] - Neumora's NMRA-511 is positioned as having a differentiated efficacy and safety profile compared to existing treatments like REXULTI and AUVELITY [8] Safety and Tolerability - No significant safety concerns were reported, with only minor cases of headache and one SAE related to hyponatremia deemed confounded by other factors [21][22] Financial Position - Neumora's current cash position is expected to support operations into the third quarter of 2027, covering all discussed catalysts [48] Other Programs - Neumora is advancing two M4 PAM compounds (NMRA-861 and NMRA-898) in phase 1 studies, with updates expected mid-2026 [40][44] - The company is also working on the KOASTAL program for navacaprant, with data readouts expected in the second quarter of 2026 [45][47] Conclusion Neumora Therapeutics is making significant strides in developing NMRA-511 for Alzheimer's disease agitation, with promising clinical data and a clear path for future studies. The company is well-positioned in a growing market, with a solid financial foundation to support its ongoing and future programs.

Travere Therapeutics (NasdaqGM:TVTX) 2026 Conference February 11, 2026 04:00 PM ET Company ParticipantsChris Cline - CFOEric Dube - President and CEOConference Call ParticipantsVamil Divan - Biopharma AnalystVamil DivanAll right, I think we're ready to get started. So, thanks everyone for joining us for this year's Biotech Summit here at Guggenheim. I'm Vamil Divan, one of the biopharma analysts here. Next up in this room, we have the Travere Therapeutics team. Next to me, Eric Dube, the President and CEO, ...

Fourth Quarter 2025 Business Review FEBRUARY 11, 2026 1 © 2026 | AURORA PROPRIETARY Cautionary statement regarding forward-looking statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws. The words "believe,ˮ "may,ˮ "will,ˮ "estimate,ˮ "continue,ˮ "anticipate,ˮ "intend,ˮ "expect,ˮ "could,ˮ "would,ˮ "project,ˮ "plan,ˮ "potential,ˮ "target,ˮ and similar expressions and variations thereof are intended to identify forward-looking statements, but ...

QuidelOrtho Fourth Quarter and Full-Year 2025 Financial Results February 11, 2026 QuidelOrtho – Proprietary & Confidential. | © 2025. All Rights Reserved. 2 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements: This presentation of QuidelOrtho Corporation ("QuidelOrtho" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly his ...

Inspire Medical Systems, Inc. February 2026 NYSE: INSP This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding potential impacts to our business associated with Inspire V reimbursement, our plans to obtain a long-term solution that would support appropriate reimbursement for Inspire V, and our ex ...

Earnings Presentation Q4 and Full-Year 2025 Results | February 11, 2026 Safe Harbor A number of forward-looking statements will be made during this presentation. Forward-looking statements are any statements that are not historical facts. These forward-looking statements are based on the current expectations of Motorola Solutions, and we can give no assurance that any future results or events discussed in these statements will be achieved. Any forward-looking statements represent our views only as of today ...

Q4 2025 Earnings Presentation February 11, 2026 Copyright 2026 Porch Group, Inc. All rights reserved Disclaimers Financial Targets Porch is providing guidance and targets for future periods in this presentation, based on current market conditions, assumptions, and expectations as of the date of this presentation. Actual results may vary due to a number of factors, and there is no guarantee that we will be able to achieve these results. Please refer to the below for important disclaimers and a description of ...

February 11, 2026 Q2 02 Safe Harbor Statement 4th Quarter & Full-Year 2025 Results This presentation and the accompanying oral presentation contain forward-looking statements and information that are based on our management's beliefs and assumptions and our manacement. The satements and information cortained in this presentation that are not purel historical are corward-looking statements within the meaning of the Private Section 21A di the Seourities Act of 1933, as amerched, and Section 21E of the Securit ...

2Q FY26 Result Presentation Mr. Todd Abbott – Chief Executive Officer North America: February 11, 2026 | Australia: February 12, 2026 ` NYSE: TBN, ASX: TBN For personal use only Disclaimer The information in this presentation includes "forward -looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which include statements on Tamboran Resources Corporation ...